Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones
Swathi Karthikeyan, … , Sarah Croessmann, Ben Ho Park
Swathi Karthikeyan, … , Sarah Croessmann, Ben Ho Park
Published February 2, 2021
Citation Information: J Clin Invest. 2021;131(6):e143557. https://doi.org/10.1172/JCI143557.
View: Text | PDF
Research Article Cell biology Oncology

Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones

  • Text
  • PDF
Abstract

Intratumor heterogeneity is an important mediator of poor outcomes in many cancers, including breast cancer. Genetic subclones frequently contribute to this heterogeneity; however, their growth dynamics and interactions remain poorly understood. PIK3CA and HER2 alterations are known to coexist in breast and other cancers. Herein, we present data that describe the ability of oncogenic PIK3CA mutant cells to induce the proliferation of quiescent HER2 mutant cells through a cell contact–mediated mechanism. Interestingly, the HER2 cells proliferated to become the major subclone over PIK3CA counterparts both in vitro and in vivo. Furthermore, this phenotype was observed in both hormone receptor–positive and –negative cell lines, and was dependent on the expression of fibronectin from mutant PIK3CA cells. Analysis of human tumors demonstrated similar HER2:PIK3CA clonal dynamics and fibronectin expression. Our study provides insight into nonrandom subclonal architecture of heterogenous tumors, which may aid the understanding of tumor evolution and inform future strategies for personalized medicine.

Authors

Swathi Karthikeyan, Ian G. Waters, Lauren Dennison, David Chu, Joshua Donaldson, Dong Ho Shin, D. Marc Rosen, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Melinda E. Sanders, Morgan V. Pantone, Riley E. Bergman, Brad A. Davidson, Sarah C. Reed, Daniel J. Zabransky, Karen Cravero, Kelly Kyker-Snowman, Berry Button, Hong Yuen Wong, Paula J. Hurley, Sarah Croessmann, Ben Ho Park

×

Figure 5

Clinical data from patients with breast cancer corroborate the role of fibronectin.

Options: View larger image (or click on image) Download as PowerPoint
Clinical data from patients with breast cancer corroborate the role of f...
(A) Immunohistochemical staining of small patient cohort for fibronectin in human breast tumors with and without PIK3CA alterations. Tumors with alterations in PIK3CA are shown in blue and those with high fibronectin are shown in red. Unaltered tumors are shown in gray. (B) Representative images of fibronectin IHC in human breast tumors with a PIK3CA (left) alteration and without a PIK3CA alteration (right). Scale bars: 100 μM. (C) Schematic of patient selection and analysis of the METABRIC data set using cBioPortal. (D) Quantification of PIK3CA alterations and alterations in other genes involved in the PI3K pathway, in breast tumors with increased fibronectin as analyzed by cBioPortal using the METABRIC data set.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts